THE ELITE UNIVERSAL
TEST BANK: ALASKA
PHARMACY
JURISPRUDENCE
(MPJE) 2026/2027
MASTERY
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The Standard of Excellence: A Research Synthesis of Alaska Pharmacy Law
○ The "Critical Axioms" Cheat Sheet & Structural Data
● PART II: THE ELITE TEST BANK
○ Tier 1 (Questions 1–28) - Foundational Syntax & Application: Hard statutory
definitions, limits, and state schedules.
○ Tier 2 (Questions 29–58) - Complex Application & Simulation: Variable-driven
operational scenarios requiring immediate regulatory triage.
○ Tier 3 (Questions 59–88) - Grandmaster Synthesis: High-stakes, multi-jurisdictional
synthesis demanding flawless clinical and legal intuition.
PART I: THE PRIMER
This document serves as the definitive training and research protocol for elite pharmacy
practitioners navigating the rapidly evolving Alaskan legal landscape. By mastering these 88
high-stakes scenarios, rote memorization is entirely replaced with the clinical intuition required
to execute 2026/2027 evidence-based and legally immaculate pharmacy standards.
The Alaska Board of Pharmacy has fundamentally restructured the practice of pharmacy,
shifting from a traditional dispensing model to an autonomous, clinical-provider framework. The
legislative passage of SB 147 (effective 2026) codified "patient care services" directly into the
practice of pharmacy, granting pharmacists independent authority to prescribe and administer
drugs and devices. Consequently, the regulatory burden has increased symmetrically;
pharmacists wielding prescriptive authority for state or federal controlled substances are now
strictly mandated to register with the Prescription Drug Monitoring Program (PDMP).
,Furthermore, Alaska's vast and unforgiving geography has catalyzed the repeal of archaic
geographical barriers, such as the 10-mile telepharmacy restriction, replacing physical proximity
mandates with rigorous, technology-driven oversight. The practitioner must synthesize these
legislative shifts—from the 120-day Continuation of Therapy (COT) lifelines to the unique Alaska
State Controlled Substance Schedules—to operate without catastrophic legal failure.
The "Critical Axioms" Cheat Sheet:
● The 120-Day COT Mandate: Under 12 AAC 52.470, if a prescriber is unreachable, a
pharmacist may provide a Continuation of Therapy (COT) for an existing, chronic,
non-controlled medication up to a strictly capped 120-day supply.
● The Biosimilar 3-Day Rule: Under AS 08.80.295, substituting an interchangeable
biological product demands the prescriber be notified within exactly 3 business days via
an electronic medical record or direct communication.
● The SB 147 Prescriptive Expansion: Effective 2026, pharmacists possess independent
prescribing authority for patient care services but MUST register with the PDMP if
prescribing or dispensing State Schedule IA-VA or Federal Schedule II-V controlled
substances.
● The PTCB-Certified Exemption: Pharmacy Technicians with National Certification
bypass legacy restrictions, legally executing final checks on non-controlled substances,
transferring non-controlled prescriptions, and clarifying missing data directly with
prescribers.
● Telepharmacy Autonomy: The antiquated 10-mile restriction is obsolete. A remote
pharmacy may operate anywhere, provided a central Alaska-licensed pharmacist verifies
every dispensed product via a secure telepharmacy system.
Structural Data: Alaska State Controlled Substance Schedules (AS 11.71)
State Schedule Federal Equivalent / Core Drug Examples Citation
Distinction
Schedule IA Highest Danger Heroin, Oxycodone,
(Synthetic/Non-syntheti Fentanyl, GHB
c Opiates)
Schedule IIA Stimulants, Methamphetamine,
Psychedelics, Cocaine, PCP,
Barbiturates Amobarbital
Schedule IIIA Appetite Suppressants, Benzphetamine,
Sedatives Glutethimide
Schedule IVA Benzodiazepines, Alprazolam (Xanax),
Ketamine Diazepam (Valium),
Ketamine
Schedule VA Anabolic Steroids, Testosterone,
Opioid Buprenorphine
Agonist/Antagonist (Suboxone)
Schedule VIA Lowest Danger Marijuana
(Tetrahydrocannabinols
)
PART II: THE ELITE TEST BANK
,Tier 1 - Foundational Syntax & Application
Q1: A patient requires an emergency refill of levothyroxine, but the prescribing practitioner is out
of the country and unreachable. Under 12 AAC 52.470, what is the MAXIMUM supply the
pharmacist may dispense as a Continuation of Therapy (COT)? A) A 30-day supply B) A
72-hour supply C) A 120-day supply D) A 90-day supply
● The Answer: C (A 120-day supply)
● Distractor Analysis:
○ A is incorrect: A 30-day supply was the legacy standard, expanding to ensure
long-term continuity of care during practitioner absences.
○ B is incorrect: The 72-hour emergency supply rule applies exclusively to institutional
emergency room dispensing of controlled substances.
○ D is incorrect: 90 days is a standard maintenance fill increment, not the statutory
emergency limit.
The Mentor's Analysis: Alaska prioritizes continuity of care for chronic, non-controlled
maintenance medications when prescribers vanish. When facing a lapsed prescription with an
unreachable prescriber, the immediate priority is bridging the patient safely. By utilizing the
120-day COT rule, you bypass the common trap of abandoning the patient.
Professional/Academic Intuition: Chronic non-controls earn a 120-day lifeline.
Q2: A pharmacist substitutes the interchangeable biological product Amjevita for Humira.
According to AS 08.80.295, the pharmacist MUST notify the prescribing practitioner of this exact
substitution within what specific timeframe? A) 24 hours B) 3 business days C) 5 business days
D) 72 hours
● The Answer: B (3 business days)
● Distractor Analysis:
○ A is incorrect: 24 hours is a common novice assumption for acute clinical
interventions, not administrative notifications.
○ C is incorrect: 5 business days is the standard in several other jurisdictions (e.g.,
Wisconsin), but is legally non-compliant in Alaska.
○ D is incorrect: 72 hours applies to PDMP error corrections, not biosimilar
substitutions.
The Mentor's Analysis: Substituting an interchangeable biological product requires swift,
documented transparency to prevent immunological overlap errors. Entering the data into a
shared Electronic Medical Record (EMR) satisfies this requirement. Professional/Academic
Intuition: Biologic substitutions demand a 3-business-day communication.
Q3: Under the 2026 implementation of SB 147, a pharmacist utilizing independent prescriptive
authority for patient care services MUST register with the controlled substance prescription
database (PDMP) if prescribing which of the following? A) Only Federal Schedule II narcotics B)
State Schedule IA through VA and Federal Schedule II through V C) Federal Schedule II
through IV only D) State Schedule IIA through IVA only
● The Answer: B (State Schedule IA through VA and Federal Schedule II through V)
● Distractor Analysis:
○ A is incorrect: This ignores lower-tier controlled substances that carry high abuse
potential.
○ C is incorrect: This represents the legacy pre-2026 PDMP reporting rule before the
statutory expansion.
○ D is incorrect: This critically misses the highest (IA) and lowest (VA) state
schedules.
, The Mentor's Analysis: SB 147 unified the PDMP registration mandate, forcing pharmacists who
prescribe to operate under the exact same comprehensive monitoring standards as physicians.
By utilizing the full scope of State and Federal schedules, you bypass the common trap of
under-reporting. Professional/Academic Intuition: Prescribe any control, register for the
PDMP.
Q4: A central pharmacy operates a remote pharmacy via a telepharmacy system. Under current
Alaska regulations, what is the MAXIMUM distance allowed between the central and remote
pharmacy? A) 10 road miles B) 50 road miles C) 100 road miles D) There is no distance
restriction
● The Answer: D (There is no distance restriction)
● Distractor Analysis:
○ A is incorrect: The 10-road-mile restriction is an obsolete legacy regulation repealed
by the Board to accommodate Alaska's unique geography.
○ B is incorrect: This is a fabricated mileage limit.
○ C is incorrect: This is a fabricated mileage limit.
The Mentor's Analysis: Alaska’s vast geography makes rigid mileage limits dangerous to public
health. The Board eliminated the 10-mile rule, relying entirely on secure digital telepharmacy
verification. Professional/Academic Intuition: Technology supersedes geography;
telepharmacy knows no borders.
Q5: A Pharmacy Technician with National Certification (PTCB) is assigned to the workflow.
Under 12 AAC 52.235, which action is this specific technician legally PERMITTED to execute?
A) Transferring a Schedule IV prescription to a competitor pharmacy B) Performing a final check
on a non-controlled substance prescription C) Verifying a telepharmacy dispensing queue D)
Providing initial patient counseling on a new medication
● The Answer: B (Performing a final check on a non-controlled substance prescription)
● Distractor Analysis:
○ A is incorrect: Federal law dictates that only pharmacists may transfer controlled
substances.
○ C is incorrect: Telepharmacy product verification is strictly a licensed pharmacist's
non-delegable duty.
○ D is incorrect: Patient counseling is a clinical pharmacist duty that cannot be
delegated to any technician.
The Mentor's Analysis: National certification elevates the technician from a data-entry clerk to a
clinical extender. They are explicitly authorized to verify standard, non-controlled fills to improve
workflow balance. Professional/Academic Intuition: PTCB certification unlocks non-control
final checks.
Q6: An Alaska pharmacist is renewing their license. They maintain a DEA registration to
prescribe. How many continuing education (CE) hours MUST be dedicated specifically to pain
management and opioid addiction? A) 1 hour B) 2 hours C) 5 hours D) 30 hours
● The Answer: B (2 hours)
● Distractor Analysis:
○ A is incorrect: 1 hour is required for immunization training, not pain management.
○ C is incorrect: This is a fabricated, excessive requirement.
○ D is incorrect: 30 hours is the total biennial CE requirement for all topics combined.
The Mentor's Analysis: The state demands that any practitioner holding the federal power to
prescribe controlled substances maintains sharp clinical awareness of opioid addiction risks.
Professional/Academic Intuition: DEA registration triggers the 2-hour opioid CE mandate.
Q7: What is the statutory retention period for all original prescription drug orders dispensed in
TEST BANK: ALASKA
PHARMACY
JURISPRUDENCE
(MPJE) 2026/2027
MASTERY
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The Standard of Excellence: A Research Synthesis of Alaska Pharmacy Law
○ The "Critical Axioms" Cheat Sheet & Structural Data
● PART II: THE ELITE TEST BANK
○ Tier 1 (Questions 1–28) - Foundational Syntax & Application: Hard statutory
definitions, limits, and state schedules.
○ Tier 2 (Questions 29–58) - Complex Application & Simulation: Variable-driven
operational scenarios requiring immediate regulatory triage.
○ Tier 3 (Questions 59–88) - Grandmaster Synthesis: High-stakes, multi-jurisdictional
synthesis demanding flawless clinical and legal intuition.
PART I: THE PRIMER
This document serves as the definitive training and research protocol for elite pharmacy
practitioners navigating the rapidly evolving Alaskan legal landscape. By mastering these 88
high-stakes scenarios, rote memorization is entirely replaced with the clinical intuition required
to execute 2026/2027 evidence-based and legally immaculate pharmacy standards.
The Alaska Board of Pharmacy has fundamentally restructured the practice of pharmacy,
shifting from a traditional dispensing model to an autonomous, clinical-provider framework. The
legislative passage of SB 147 (effective 2026) codified "patient care services" directly into the
practice of pharmacy, granting pharmacists independent authority to prescribe and administer
drugs and devices. Consequently, the regulatory burden has increased symmetrically;
pharmacists wielding prescriptive authority for state or federal controlled substances are now
strictly mandated to register with the Prescription Drug Monitoring Program (PDMP).
,Furthermore, Alaska's vast and unforgiving geography has catalyzed the repeal of archaic
geographical barriers, such as the 10-mile telepharmacy restriction, replacing physical proximity
mandates with rigorous, technology-driven oversight. The practitioner must synthesize these
legislative shifts—from the 120-day Continuation of Therapy (COT) lifelines to the unique Alaska
State Controlled Substance Schedules—to operate without catastrophic legal failure.
The "Critical Axioms" Cheat Sheet:
● The 120-Day COT Mandate: Under 12 AAC 52.470, if a prescriber is unreachable, a
pharmacist may provide a Continuation of Therapy (COT) for an existing, chronic,
non-controlled medication up to a strictly capped 120-day supply.
● The Biosimilar 3-Day Rule: Under AS 08.80.295, substituting an interchangeable
biological product demands the prescriber be notified within exactly 3 business days via
an electronic medical record or direct communication.
● The SB 147 Prescriptive Expansion: Effective 2026, pharmacists possess independent
prescribing authority for patient care services but MUST register with the PDMP if
prescribing or dispensing State Schedule IA-VA or Federal Schedule II-V controlled
substances.
● The PTCB-Certified Exemption: Pharmacy Technicians with National Certification
bypass legacy restrictions, legally executing final checks on non-controlled substances,
transferring non-controlled prescriptions, and clarifying missing data directly with
prescribers.
● Telepharmacy Autonomy: The antiquated 10-mile restriction is obsolete. A remote
pharmacy may operate anywhere, provided a central Alaska-licensed pharmacist verifies
every dispensed product via a secure telepharmacy system.
Structural Data: Alaska State Controlled Substance Schedules (AS 11.71)
State Schedule Federal Equivalent / Core Drug Examples Citation
Distinction
Schedule IA Highest Danger Heroin, Oxycodone,
(Synthetic/Non-syntheti Fentanyl, GHB
c Opiates)
Schedule IIA Stimulants, Methamphetamine,
Psychedelics, Cocaine, PCP,
Barbiturates Amobarbital
Schedule IIIA Appetite Suppressants, Benzphetamine,
Sedatives Glutethimide
Schedule IVA Benzodiazepines, Alprazolam (Xanax),
Ketamine Diazepam (Valium),
Ketamine
Schedule VA Anabolic Steroids, Testosterone,
Opioid Buprenorphine
Agonist/Antagonist (Suboxone)
Schedule VIA Lowest Danger Marijuana
(Tetrahydrocannabinols
)
PART II: THE ELITE TEST BANK
,Tier 1 - Foundational Syntax & Application
Q1: A patient requires an emergency refill of levothyroxine, but the prescribing practitioner is out
of the country and unreachable. Under 12 AAC 52.470, what is the MAXIMUM supply the
pharmacist may dispense as a Continuation of Therapy (COT)? A) A 30-day supply B) A
72-hour supply C) A 120-day supply D) A 90-day supply
● The Answer: C (A 120-day supply)
● Distractor Analysis:
○ A is incorrect: A 30-day supply was the legacy standard, expanding to ensure
long-term continuity of care during practitioner absences.
○ B is incorrect: The 72-hour emergency supply rule applies exclusively to institutional
emergency room dispensing of controlled substances.
○ D is incorrect: 90 days is a standard maintenance fill increment, not the statutory
emergency limit.
The Mentor's Analysis: Alaska prioritizes continuity of care for chronic, non-controlled
maintenance medications when prescribers vanish. When facing a lapsed prescription with an
unreachable prescriber, the immediate priority is bridging the patient safely. By utilizing the
120-day COT rule, you bypass the common trap of abandoning the patient.
Professional/Academic Intuition: Chronic non-controls earn a 120-day lifeline.
Q2: A pharmacist substitutes the interchangeable biological product Amjevita for Humira.
According to AS 08.80.295, the pharmacist MUST notify the prescribing practitioner of this exact
substitution within what specific timeframe? A) 24 hours B) 3 business days C) 5 business days
D) 72 hours
● The Answer: B (3 business days)
● Distractor Analysis:
○ A is incorrect: 24 hours is a common novice assumption for acute clinical
interventions, not administrative notifications.
○ C is incorrect: 5 business days is the standard in several other jurisdictions (e.g.,
Wisconsin), but is legally non-compliant in Alaska.
○ D is incorrect: 72 hours applies to PDMP error corrections, not biosimilar
substitutions.
The Mentor's Analysis: Substituting an interchangeable biological product requires swift,
documented transparency to prevent immunological overlap errors. Entering the data into a
shared Electronic Medical Record (EMR) satisfies this requirement. Professional/Academic
Intuition: Biologic substitutions demand a 3-business-day communication.
Q3: Under the 2026 implementation of SB 147, a pharmacist utilizing independent prescriptive
authority for patient care services MUST register with the controlled substance prescription
database (PDMP) if prescribing which of the following? A) Only Federal Schedule II narcotics B)
State Schedule IA through VA and Federal Schedule II through V C) Federal Schedule II
through IV only D) State Schedule IIA through IVA only
● The Answer: B (State Schedule IA through VA and Federal Schedule II through V)
● Distractor Analysis:
○ A is incorrect: This ignores lower-tier controlled substances that carry high abuse
potential.
○ C is incorrect: This represents the legacy pre-2026 PDMP reporting rule before the
statutory expansion.
○ D is incorrect: This critically misses the highest (IA) and lowest (VA) state
schedules.
, The Mentor's Analysis: SB 147 unified the PDMP registration mandate, forcing pharmacists who
prescribe to operate under the exact same comprehensive monitoring standards as physicians.
By utilizing the full scope of State and Federal schedules, you bypass the common trap of
under-reporting. Professional/Academic Intuition: Prescribe any control, register for the
PDMP.
Q4: A central pharmacy operates a remote pharmacy via a telepharmacy system. Under current
Alaska regulations, what is the MAXIMUM distance allowed between the central and remote
pharmacy? A) 10 road miles B) 50 road miles C) 100 road miles D) There is no distance
restriction
● The Answer: D (There is no distance restriction)
● Distractor Analysis:
○ A is incorrect: The 10-road-mile restriction is an obsolete legacy regulation repealed
by the Board to accommodate Alaska's unique geography.
○ B is incorrect: This is a fabricated mileage limit.
○ C is incorrect: This is a fabricated mileage limit.
The Mentor's Analysis: Alaska’s vast geography makes rigid mileage limits dangerous to public
health. The Board eliminated the 10-mile rule, relying entirely on secure digital telepharmacy
verification. Professional/Academic Intuition: Technology supersedes geography;
telepharmacy knows no borders.
Q5: A Pharmacy Technician with National Certification (PTCB) is assigned to the workflow.
Under 12 AAC 52.235, which action is this specific technician legally PERMITTED to execute?
A) Transferring a Schedule IV prescription to a competitor pharmacy B) Performing a final check
on a non-controlled substance prescription C) Verifying a telepharmacy dispensing queue D)
Providing initial patient counseling on a new medication
● The Answer: B (Performing a final check on a non-controlled substance prescription)
● Distractor Analysis:
○ A is incorrect: Federal law dictates that only pharmacists may transfer controlled
substances.
○ C is incorrect: Telepharmacy product verification is strictly a licensed pharmacist's
non-delegable duty.
○ D is incorrect: Patient counseling is a clinical pharmacist duty that cannot be
delegated to any technician.
The Mentor's Analysis: National certification elevates the technician from a data-entry clerk to a
clinical extender. They are explicitly authorized to verify standard, non-controlled fills to improve
workflow balance. Professional/Academic Intuition: PTCB certification unlocks non-control
final checks.
Q6: An Alaska pharmacist is renewing their license. They maintain a DEA registration to
prescribe. How many continuing education (CE) hours MUST be dedicated specifically to pain
management and opioid addiction? A) 1 hour B) 2 hours C) 5 hours D) 30 hours
● The Answer: B (2 hours)
● Distractor Analysis:
○ A is incorrect: 1 hour is required for immunization training, not pain management.
○ C is incorrect: This is a fabricated, excessive requirement.
○ D is incorrect: 30 hours is the total biennial CE requirement for all topics combined.
The Mentor's Analysis: The state demands that any practitioner holding the federal power to
prescribe controlled substances maintains sharp clinical awareness of opioid addiction risks.
Professional/Academic Intuition: DEA registration triggers the 2-hour opioid CE mandate.
Q7: What is the statutory retention period for all original prescription drug orders dispensed in
